Lifestyle modification in NAFLD/NASH: Facts and figures

Kate Hallsworth, Leon A Adams, Kate Hallsworth, Leon A Adams

Abstract

The development of non-alcoholic fatty liver disease is closely linked to lifestyle factors, namely excessive caloric intake coupled with reduced physical activity and exercise. This review aims to examine the evidence behind lifestyle change as a tool to improve hepatic steatosis and liver histology in patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Furthermore, potential barriers to adopting lifestyle changes and strategies to overcome these barriers in the clinical setting are discussed.

Keywords: diet; lifestyle; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; physical activity/exercise; weight loss.

© 2019 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).

Figures

Fig. 1
Fig. 1
Summary of the lifestyle treatment options through the course of NAFLD (modified from115). NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis.
Fig. 2
Fig. 2
Extrahepatic benefits of physical activity and exercise for patients with NAFLD. Physical activity and exercise offer a host of extrahepatic benefits for patients with NAFLD across the disease spectrum and are useful tools to aid weight-loss maintenance. Increasing cardiorespiratory fitness and muscle strength can help to maintain and improve the ability to perform day-to-day activities and thus improve quality of life. NAFLD, non-alcoholic fatty liver disease.
Fig. 3
Fig. 3
Useful techniques to support patients to make and sustain lifestyle changes,,,

References

    1. Collaboration NCDRF Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet. 2016;387:1377–1396.
    1. Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:389–398.
    1. Gepner Y, Shelef I, Komy O, Cohen N, Schwarzfuchs D, Bril N. The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content. J Hepatol. 2019;71:379–388.
    1. St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. J Gastroenterol Hepatol. 2009;24:399–407.
    1. Sun WH, Song MQ, Jiang CQ, Xin YN, Ma JL, Liu YX. Lifestyle intervention in non-alcoholic fatty liver disease in Chengyang District, Qingdao, China. World J Hepatol. 2012;4:224–230.
    1. Wong VW, Chan RS, Wong GL, Cheung BH, Chu WC, Yeung DK. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol. 2013;59:536–542.
    1. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121–129.
    1. Eckard C, Cole R, Lockwood J, Torres DM, Williams CD, Shaw JC. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Ther Adv Gastroenterol. 2013;6:249–259.
    1. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol. 1997;27:103–107.
    1. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367–378. e365.
    1. Wong VW, Wong GL, Chan RS, Shu SS, Cheung BH, Li LS. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol. 2018;69:1349–1356.
    1. Mazzotti A, Caletti MT, Brodosi L, Di Domizio S, Forchielli ML, Petta S. An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. J Hepatol. 2018;69:1155–1163.
    1. Shen J, Wong GL, Chan HL, Chan HY, Yeung DK, Chan RS. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Aliment Pharmacol Ther. 2014;39:532–539.
    1. Haufe S, Haas V, Utz W, Birkenfeld AL, Jeran S, Bohnke J. Long-lasting improvements in liver fat and metabolism despite body weight regain after dietary weight loss. Diabetes Care. 2013;36:3786–3792.
    1. Eslamparast T, Montano-Loza AJ, Raman M, Tandon P. Sarcopenic obesity in cirrhosis-The confluence of 2 prognostic titans. Liver Int. 2018;38:1706–1717.
    1. European Association for the Study of the Liver Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70:172–193.
    1. Berzigotti A, Albillos A, Villanueva C, Genesca J, Ardevol A, Augustin S. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study. Hepatology. 2017;65:1293–1305.
    1. Luukkonen PK, Sadevirta S, Zhou Y, Kayser B, Ali A, Ahonen L. Saturated Fat Is More Metabolically Harmful for the Human Liver Than Unsaturated Fat or Simple Sugars. Diabetes Care. 2018;41:1732–1739.
    1. Yki-Jarvinen H. Nutritional Modulation of Non-Alcoholic Fatty Liver Disease and Insulin Resistance. Nutrients. 2015;7:9127–9138.
    1. Mardinoglu A, Wu H, Bjornson E, Zhang C, Hakkarainen A, Rasanen SM. An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans. Cell Metab. 2018;27:559–571.e555.
    1. Alferink LJ, Kiefte-de Jong JC, Erler NS, Veldt BJ, Schoufour JD, de Knegt RJ. Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: the Rotterdam Study. Gut. 2018;68:1088–1098.
    1. Markova M, Pivovarova O, Hornemann S, Sucher S, Frahnow T, Wegner K. Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes. Gastroenterology. 2017;152:571–585.e578.
    1. Skytte MJ, Samkani A, Petersen AD, Thomsen MN, Astrup A, Chabanova E. A carbohydrate-reduced high-protein diet improves HbA1c and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trial. Diabetologia. 2019;Jul 23 [Epub ahead of print]
    1. Kirk E, Reeds DN, Finck BN, Mayurranjan SM, Patterson BW, Klein S. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology. 2009;136:1552–1560.
    1. Haufe S, Engeli S, Kast P, Bohnke J, Utz W, Haas V. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology. 2011;53:1504–1514.
    1. Schwimmer JB, Ugalde-Nicalo P, Welsh JA, Angeles JE, Cordero M, Harlow KE. Effect of a Low Free Sugar Diet vs Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys: A Randomized Clinical Trial. JAMA. 2019;321:256–265.
    1. Schwarz JM, Noworolski SM, Erkin-Cakmak A, Korn NJ, Wen MJ, Tai VW. Effects of Dietary Fructose Restriction on Liver Fat, De Novo Lipogenesis, and Insulin Kinetics in Children With Obesity. Gastroenterology. 2017;153:743–752.
    1. Johnston RD, Stephenson MC, Crossland H, Cordon SM, Palcidi E, Cox EF. No difference between high-fructose and high-glucose diets on liver triacylglycerol or biochemistry in healthy overweight men. Gastroenterology. 2013;145:1016–1025.e1012.
    1. Zelber-Sagi S, Salomone F, Mlynarsky L. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms. Liver Int. 2017;37:936–949.
    1. Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018;378:e34.
    1. Properzi C, O'Sullivan TA, Sherriff JL, Ching HL, Jeffrey GP, Buckley RF. Ad Libitum Mediterranean and Low-Fat Diets Both Significantly Reduce Hepatic Steatosis: A Randomized Controlled Trial. Hepatology. 2018;68:1741–1754.
    1. Ryan MC, Itsiopoulos C, Thodis T, Ward G, Trost N, Hofferberth S. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol. 2013;59:138–143.
    1. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–1402.
    1. Mitchell T, Jeffrey GP, de Boer B, MacQuillan G, Garas G, Ching H. Type and Pattern of Alcohol Consumption is Associated With Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease. Am J Gastroenterol. 2018;113:1484–1493.
    1. Hagström H, Nasr P, Ekstedt M, Kechagias S, Önnerhag K, Nilsson E. Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease. Scand J Gastroenterol. 2017;52:159–165.
    1. Ajmera V, Belt P, Wilson LA, Gill RM, Loomba R, Kleiner DE. Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis. Clin Gastroenterol Hepatol. 2018;16:1511–1520.
    1. Åberg F, Puukka P, Salomaa V, Männistö S, Lundqvist A, Valsta L. Risks of Light and Moderate Alcohol Use in Fatty Liver Disease: Follow-Up of Population Cohorts. Hepatology. 2019, Jul 19 [Epub ahead of print]
    1. Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, Castellanos M, Aller-de la Fuente R, Metwally M. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. Gastroenterology. 2018;155:443–457.
    1. Nelson JE, Roth CL, Wilson LA, Yates KP, Aouizerat B, Morgan-Stevenson V. Vitamin D Deficiency Is Associated With Increased Risk of Non-alcoholic Steatohepatitis in Adults With Non-alcoholic Fatty Liver Disease: Possible Role for MAPK and NF-κB? Am J Gastroenterol. 2016;111:852–863.
    1. Black LJ, Jacoby P, She Ping-Delfos WC, Mori TA, Beilin LJ, Olynyk JK. Low serum 25-hydroxyvitamin D concentrations associate with non-alcoholic fatty liver disease in adolescents independent of adiposity. J Gastroenterol Hepatol. 2014;29:1215–1222.
    1. Geier A, Eichinger M, Stirnimann G, Semela D, Tay F, Seifert B. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. Scand J Gastroenterol. 2018;53:1114–1120.
    1. Kitson MT, Pham A, Gordon A, Kemp W, SK R. High-dose vitamin D supplementation and liver histology in NASH. Gut. 2016;65:717–718.
    1. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–1685.
    1. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305:1659–1668.
    1. Bril F, Biernacki DM, Kalavalapalli S, Lomonaco R, Subbarayan SK, Lai J. Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care. 2019;42:1481–1488.
    1. Bjelakovic G, Nikolova D, Gluud C. Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: do we have evidence for lack of harm? PLoS One. 2013;8:e74558.
    1. Yashin A, Yashin Y, Wang JY, Nemzer B. Antioxidant and Antiradical Activity of Coffee. Antioxidants. 2013;2:230–245.
    1. Bambha K, Wilson LA, Unalp A, Loomba R, Neuschwander-Tetri BA, Brunt EM. Coffee consumption in patients with NAFLD with lower insulin resistance is associated with lower risk of severe fibrosis. Liver Int. 2014;34:1250–1258.
    1. Alferink LJM, Fittipaldi J, Kiefte-de Jong JC, Taimr P, Hansen BE, Metselaar HJ. Coffee and herbal tea consumption is associated with lower liver stiffness in the general population: The Rotterdam study. J Hepatol. 2017;67:339–348.
    1. Graeter T, Niedermayer PC, Mason RA, Oeztuerk S, Haenle MM, Koenig W. Coffee consumption and NAFLD: a community based study on 1223 subjects. BMC Res Notes. 2015;3:640.
    1. Setiawan VW, Wilkens LR, Lu SC, Hernandez BY, Le Marchand L, Henderson BE. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology. 2015;148:118–125.
    1. Loffredo L, Del Ben M, Perri L, Carnevale R, Nocella C, Catasca E. Effects of dark chocolate on NOX-2-generated oxidative stress in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2016 Aug;44:279–286. Epub 2016 Jun 6 2016;44:279-286.
    1. Bozzetto L, Prinster A, Annuzzi G, Costagliola L, Mangione A, Vitelli A. Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients. Diabetes Care. 2012;35:1429–1435.
    1. Goodpaster BH, Delany JP, Otto AD, Kuller L, Vockley J, South-Paul JE. Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: a randomized trial. JAMA. 2010;304:1795–1802.
    1. Shah K, Stufflebam A, Hilton TN, Sinacore DR, Klein S, Villareal DT. Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. Obesity (Silver Spring) 2009;17:2162–2168.
    1. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–357.
    1. Hashida R, Kawaguchi T, Bekki M, Omoto M, Matsuse H, Nago T. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. J Hepatol. 2017;66:142–152.
    1. Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;57:157–166.
    1. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106:388–391.
    1. ACSM . 5th ed. Lippincott Williams and Wilkins; 2006. ACSM's Resource Manual for Guidelines for Exercise Testing and Prescription.
    1. Grontved A, Hu FB. Television viewing and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: a meta-analysis. JAMA. 2011;305:2448–2455.
    1. Dunstan DW, Salmon J, Healy GN, Shaw JE, Jolley D, Zimmet PZ. Association of television viewing with fasting and 2-h postchallenge plasma glucose levels in adults without diagnosed diabetes. Diabetes Care. 2007;30:516–522.
    1. Dunstan D, Salmon J, Owen N, Armstrong T, Zimmet P, Welborn T. Associations of TV viewing and physical activity with the metabolic syndrome in Australian adults. Diabetologia. 2005;48:2254–2261.
    1. Bowden Davies KA, Sprung VS, Norman JA, Thompson A, Mitchell KL, Harrold JOA. Physical Activity and Sedentary Time: Association with Metabolic Health and Liver Fat. Med Sci Sports Exerc. 2019;51:1169–1177.
    1. Ryu S, Chang Y, Jung HS, Yun KE, Kwon MJ, Choi Y. Relationship of sitting time and physical activity with non-alcoholic fatty liver disease. J Hepatol. 2015;63:1229–1237.
    1. Healy GN, Dunstan DW, Salmon J, Cerin E, Shaw JE, Zimmet PZ. Breaks in Sedentary Time: Beneficial associations with metabolic risk. Diabetes Care. 2008;31:661–666.
    1. ACSM American College of Sports Medicine Position Stand. Appropriate physical activity intervention for weight loss and weight regain for adults. Med Sci Sports Exerc. 2009;41:459–471.
    1. Department of Health UK Physical Activity Guidelines. 2011. [cited 2012 February]; Available from:
    1. Hsieh SD, Yoshinaga H, Muto T, Sakurai Y. Regular Physical Activity and Coronary Risk Factors in Japanese Men. Circulation. 1998;97:661–665.
    1. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Zvibel I, Goldiner I. Role of leisure-time physical activity in nonalcoholic fatty liver disease: A population-based study. Hepatology. 2008;48:1791–1798.
    1. Perseghin G, Lattuada G, De Cobelli F, Ragogna F, Ntali G, Esposito A. Habitual Physical Activity Is Associated With Intrahepatic Fat Content in Humans. Diabetes Care. 2007;30:683–688.
    1. Krasnoff JB, Painter PL, Wallace JP, Bass NM, Merriman RB. Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. Hepatology. 2008;47:1158–1166.
    1. Hallsworth K, Thoma C, Moore S, Ploetz T, Anstee QM, Taylor R. Non-alcoholic fatty liver disease is associated with higher levels of objectively measured sedentary behaviour and lower levels of physical activity than matched healthy controls. Frontline Gastroenterol. 2015;6:44–51.
    1. Keating SE, George J, Johnson NA. The benefits of exercise for patients with non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9:1247–1250.
    1. Gerage AM, Ritti-Dias RM, Balagopal PB, Conceição RDO, Umpierre D, Santos RD. Physical activity levels and hepatic steatosis: A longitudinal follow-up study in adults. J Gastroenterol Hepatol. 2018;33:741–746.
    1. Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol. 2011;106:460–468.
    1. Oh S, Shida T, Yamagishi K, Tanaka K, So R, Tsujimoto T. Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: a retrospective study. Hepatology. 2015;61:1205–1215.
    1. Kwak MS, Kim D, Chung GE, Kim W, Kim YJ, Yoon JH. Role of physical activity in nonalcoholic fatty liver disease in terms of visceral obesity and insulin resistance. Liver Int. 2015;35:944–952.
    1. Kwak MS, Kim D. Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity. Korean J Intern Med. 2018;33:64–74.
    1. Keating SE, Hackett DA, Parker HM, O’Connor HT, Gerofi JA, Sainsbury A. Effect of aerobic exercise training dose on liver fat and visceral adiposity. J Hepatol. 2015;63:174–182.
    1. Trenell MI, Hollingsworth KG, Lim EL, Taylor R. Increased daily walking improves lipid oxidation without changes in mitochondrial function in type 2 diabetes. Diabetes Care. 2008;31:1644–1649.
    1. Carels RA, Darby LA, Rydin S, Douglass OM, Cacciapaglia HM, O'Brien WH. The relationship between self-monitoring, outcome expectancies, difficulties with eating and exercise, and physical activity and weight loss treatment outcomes. Ann Behav Med. 2005;30:182–190.
    1. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol. 2012;56:255–266.
    1. Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;57:157–166.
    1. Hallsworth K, Thoma C, Hollingsworth KG, Cassidy S, Anstee QM, Day CP. Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: a randomized controlled trial. Clin Sci. 2015;129:1097–1105.
    1. Katsagoni CN, Georgoulis M, Papatheodoridis GV, Panagiotakos DB, Kontogianni MD. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. Metabolism. 2017;68:119–132.
    1. Zhang HJ, He J, Pan LL, Ma ZM, Han CK, Chen CS. Effects of Moderate and Vigorous Exercise on Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial. JAMA Intern Med. 2016;176:1074–1082.
    1. Perri MG, Anton SD, Durning PE, Ketterson TU, Sydeman SJ, Berlant NE. Adherence to exercise prescriptions: effects of prescribing moderate versus higher levels of intensity and frequency. Health Psychol. 2002;21:452–458.
    1. Zhang HJ, Pan LL, Ma ZM, Chen Z, Huang ZF, Sun Q. Long-term effect of exercise on improving fatty liver and cardiovascular risk factors in obese adults: A 1-year follow-up study. Diabetes Obes Metab. 2016;19:284–289.
    1. Pugh CJ, Sprung VS, Jones H, Richardson P, Shojaee-Moradie F, Umpleby AM. Exercise-induced improvements in liver fat and endothelial function are not sustained 12 months following cessation of exercise supervision in nonalcoholic fatty liver disease. Int J Obes. 2016;40:1927–1930.
    1. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149:389–397. e310.
    1. Gibala MJ, Little JP, Macdonald MJ, Hawley JA. Physiological adaptations to low-volume, high-intensity interval training in health and disease. J Physiol. 2012;590:1077–1084.
    1. Guiraud T, Nigam A, Juneau M, Meyer P, Gayda M, Bosquet L. Acute Responses to High-Intensity Intermittent Exercise in CHD Patients. Med Sci Sports Exerc. 2011;43:211–217.
    1. Coquart JB, Lemaire C, Dubart AE, Luttembacher DP, Douillard C, Garcin M. Intermittent versus continuous exercise: effects of perceptually lower exercise in obese women. Med Sci Sports Exerc. 2008;40:1546–1553.
    1. Larose J, Sigal RJ, Boule NG, Wells GA, Prud'Homme D, Fortier MS. Effect of Exercise Training on Physical Fitness in Type II Diabetes Mellitus. Med Sci Sports Exerc. 2010;42:1439–1447.
    1. Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Taylor R. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut. 2011;60:1278–1283.
    1. Gordon BA, Benson AC, Bird SR, Fraser SF. Resistance training improves metabolic health in type 2 diabetes: A systematic review. Diabetes Res Clin Pract. 2009;83:157–175.
    1. Schuenke M, Mikat R, McBride J. Effect of an acute period of resistance exercise on excess post-exercise oxygen consumption: implications for body mass management. Eur J Appl Physiol. 2002;86:411–417.
    1. Houghton D, Thoma C, Hallsworth K, Cassidy S, Hardy T, Burt AD. Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2017;15:96–102.
    1. O'Gorman P. Abstract presented at ILC. 2019. Significant regression in fibrosis in paired liver biopsies following a 12-week aerobic exercise intervention in NAFLD.
    1. Spengler EK, O'Leary JG, Te HS, Rogal S, Pillai AA, Al-Osaimi A. Liver Transplantation in the Obese Cirrhotic Patient. Transplantation. 2017;101:2288–2296.
    1. Macías-Rodríguez RU, Ruiz-Margáin A, Román-Calleja BM, Moreno-Tavarez E, Weber-Sangri L, González-Arellano MF. Exercise prescription in patients with cirrhosis: Recommendations for clinical practice. Rev Gastroenterol Mex. 2019;Jun 28 [pii: S0375-0906(19)30066-7. Epub ahead of print]
    1. Wallen MP, Skinner TL, Pavey TG, Hall A, Macdonald GA, Coombes JS. Safety, adherence and efficacy of exercise training in solid-organ transplant candidates: A systematic review. Transplant Rev (Orlando) 2016;30:218–226.
    1. Williams FR, Vallance A, Faulkner T, Towey J, Durman S, Kyte D. Home-Based Exercise in Patients Awaiting Liver Transplantation: A Feasibility Study. Liver Transpl. 2019;25:995–1006.
    1. Macías-Rodríguez RU, Ilarraza-Lomelí H, Ruiz-Margáin A, Ponce-de-León-Rosales S, Vargas-Vorácková F, García-Flores O. Changes in Hepatic Venous Pressure Gradient Induced by Physical Exercise in Cirrhosis: Results of a Pilot Randomized Open Clinical Trial. Clin Transl Gastroenterol. 2016;7:180.
    1. Avery L, Exley C, McPherson S, Trenell MI, Anstee QM, Hallsworth K. Lifestyle Behavior Change in Patients With Nonalcoholic Fatty Liver Disease: A Qualitative Study of Clinical Practice. Clin Gastroenterol Hepatol. 2017;15:1968–1971.
    1. Zelber-Sagi S. Minding the Gap Between Clinical Trials and Treatment With the Mediterranean Dietary Pattern for Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2019;17:1248–1250.
    1. Bellentani S, Grave R, Suppini A, Marchesini G, (FLIN) FLIN Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. Hepatology. 2008;47:746–754.
    1. Haigh L, Bremner S, Houghton D, Henderson E, Avery L, Hardy T. Barriers and Facilitators to Mediterranean Diet Adoption by Patients With Nonalcoholic Fatty Liver Disease in Northern Europe. Clin Gastroenterol Hepatol. 2019;17:1364–1371.
    1. Hallsworth K, Dombrowski SU, McPherson S, Anstee QM, Avery L. Using the theoretical domains framework to identify barriers and enabling factors to implementation of guidance for the diagnosis and management of nonalcoholic fatty liver disease: a qualitative study. Transl Behav Med. 2019 [pii:ibz080.Epub ahead of print]
    1. Hallsworth K, Avery L, Trenell MI. Targeting Lifestyle Behavior Change in Adults with NAFLD During a 20-min Consultation: Summary of the Dietary and Exercise Literature. Curr Gastroenterol Rep. 2016;18:11.
    1. Avery L, Flynn D, Dombrowski SU, van Wersch A, Sniehotta FF, Trenell MI. Successful behavioural strategies to increase physical activity and improve glucose control in adults with Type 2 diabetes. Diabet Med. 2015;32:1058–1062.
    1. Avery L, Flynn D, van Wersch A, Sniehotta FF, Trenell MI. Changing physical activity behavior in type 2 diabetes: a systematic review and meta-analysis of behavioral interventions. Diabetes Care. 2012;35:2681–2689.
    1. Atkins L, Michie S. Designing interventions to change eating behaviours. Proc Nutr Soc. 2015;74:164–170.
    1. Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67:829–846.
    1. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6:42.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться